A phase 3 open-label, randomized multicenter study to evaluate efficacy and safety of secukinumab in pediatric patients with moderate to severe plaque psoriasis: 24-week resultsNina Magnolo, Manmath Patekar, John Browning et al.|Journal of the American Academy of Dermatology|2021Cited by 50